Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Prices 5.5M Share Offering

NEW YORK (GenomeWeb News) – Rosetta Genomics has priced a public offering of 5.5 million shares of common stock at $5 per share, the firm said today.

The microRNA diagnostics developer said it expects gross proceeds from the offering to be around $27.5 million. It expects to close the financing on or around Aug. 8, and it has granted underwriters an option to purchase 825,000 shares to cover over-allotments.

Rosetta said it would use proceeds to fund operations and general corporate purposes, as well as to repay debt, provide working capital, defend its intellectual property, and support R&D efforts, among other uses.

Rosetta's shares were down 15 percent at $4.90 in Friday morning trade on the Nasdaq.

Its stock price has fallen sharply over the past two weeks, and was down 31 percent for the month of July. The recent decline follows a jump in the firm's shares in late May after it had effected a one-for-15 reverse split, enabling the firm to regain Nasdaq compliance.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.